School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Syst Rev. 2020 Aug 3;9(1):170. doi: 10.1186/s13643-020-01432-4.
The World Health Organization declared on March 11, 2020, that the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has escalated from epidemic into pandemic. As the initial outbreak area, China has taken multiple active measures to deal with the epidemic. Updated versions of diagnosis and treatment guideline for novel coronavirus (COVID-19) patients have been issued, and traditional Chinese herbal medicine has been recommended as a treatment. The objective of this study will be to summarize the recommendations in current clinical practice guidelines about the use of traditional Chinese herbal medicine for COVID-19 patients. We will also evaluate and report on the methodological and reporting quality of these guidelines.
In this systematic review, we will search for guidelines, expert consensuses, and policy documents published since December 2019 in electronic databases (e.g., PubMed, EMBASE, and Chinese databases) and on websites of governments or organizations (e.g., The National Guideline Clearinghouse [NGC], Guidelines International Network [GIN], National Institute for Health and Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network [SIGN], and WHO). Eligible documents will be independently selected, and relevant data will be independently extracted by two reviewers. We will also independently evaluate the methodological quality and reporting quality of the included guidelines, using the Appraisal of Guidelines for REsearch & Evaluation (AGREE) II tool and Reporting Items for Practice Guidelines in Healthcare (RIGHT) statement, respectively. Any discrepancies will be discussed and resolved through discussion among the reviewers. We will use the extracted information to summarize their recommendations for traditional Chinese herbal formulae and Chinese patent medicine for COVID-19 patients and to summarize the strength and quality of these recommendations with reference to the results of AGREE II and RIGHT tools.
This review will summarize the recommendations in current clinical practice guidelines and provide insight into the implementation strategies for traditional Chinese herbal medicine in COVID-19 patients.
PROSPERO CRD42020179205.
世界卫生组织于 2020 年 3 月 11 日宣布，严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）的传播已从流行上升为大流行。作为最初的爆发地区，中国已采取多项积极措施应对疫情。已发布了新型冠状病毒（COVID-19）患者诊断和治疗指南的更新版本，并推荐使用中药进行治疗。本研究的目的将是总结当前临床实践指南中关于 COVID-19 患者使用中药的建议。我们还将评估并报告这些指南的方法学和报告质量。
在这项系统评价中，我们将搜索自 2019 年 12 月以来发表的指南、专家共识和政策文件，检索电子数据库（如 PubMed、EMBASE 和中文数据库）和政府或组织的网站（如国家指南清除中心[NGC]、指南国际网络[GIN]、国家卫生与临床卓越研究所[NICE]、苏格兰校际指南网络[SIGN]和世界卫生组织[WHO]）。合格的文件将由两名评审员独立选择，相关数据将由两名评审员独立提取。我们还将分别使用评估研究和评估指南（AGREE II）工具和医疗保健实践指南报告项目（RIGHT）声明独立评估纳入指南的方法学质量和报告质量。任何差异都将通过评审员之间的讨论来解决。我们将使用提取的信息总结他们对 COVID-19 患者使用中药方剂和中药专利药的建议，并参考 AGREE II 和 RIGHT 工具的结果总结这些建议的强度和质量。
本综述将总结当前临床实践指南中的建议，并深入了解 COVID-19 患者中药的实施策略。
PROSPERO CRD42020179205。
